Compass Therapeutics, Inc. (CMPX) · Nov 20, 2026 · Delisting
Nasdaq deficiency — Below $1.00 for 30 business days; cure deadline May 18, 2027
Compass Therapeutics received a Nasdaq deficiency notice after 30 days below $1, creating a six-month compliance clock and reverse-split risk.
Compass is a clinical-stage oncology biotech preparing a potential BLA for tovecimig while advancing earlier-stage antibody programs; its latest update reported $163 million in cash and marketable securities, with operations expected to be funded into 2028. This is a listing problem, not a clinical or operating setback. Nasdaq says Compass has been below the $1.00 minimum bid price for 30 consecutive business days, though the stock remains listed for now.
The immediate pressure is manageable, but the capital-markets risk is real. Compass gets until May 18, 2027 to regain compliance, requiring at least 10 consecutive business days at or above $1.00. 〔0〕 The company has cash runway according to its latest update, so this does not signal an imminent funding crisis; however, a Nasdaq deficiency can complicate future financing and investor access while management is already navigating a more demanding regulatory path for tovecimig.
A reverse split is now an explicit contingency, not just a theoretical possibility. If the share price does not recover, Compass may seek a second compliance period and has said it may use a reverse stock split to cure the deficiency. 〔1〕 That would address the listing rule mechanically, but it would not improve the underlying pipeline or resolve the regulatory uncertainty around the lead program.
Bottom line: The filing adds a meaningful market-structure and financing complication to an otherwise funded clinical-development story. It is not an immediate delisting or business failure, but it makes a reverse split and continued Nasdaq compliance issues part of the company’s near-term roadmap.
Nasdaq compliance deadline, May 18, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!